We Venture Capital

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.

Capitainer AB, established in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacture of innovative blood collection devices. Their flagship product enables patients to safely and accurately collect predefined volumes of dried blood spots at home, reducing the need for travel and healthcare resources traditionally spent on blood sampling. This technology offers significant cost savings and environmental benefits for healthcare providers managing large numbers of conventional blood samples annually.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.